The key application of serum tumor markers in testicular cancer: a review and update

Kishore G. Banerjee*, Muhammad Haziq A. Shamsul Azlan, Logeswaran Kalaiarasu, Haifa S. Hasrol Nizam

INTRODUCTION

Testicular cancer is a curable form of solid malignancy affecting males globally. Over the past thirty to forty years, the incidence of testicular cancer has been increasing progressively. According to global cancer observatory (GLOBOCAN) by WHO, incidences of testicular cancer worldwide reported are on the rise from over 52,000 cases in 2008 to 55,266 cases in 2012.1 The sharp increase was observed in 2018 (71,105 cases) according to the latest update by the GLOBOCAN in 2019.

Testicular cancer had been affecting primarily caucasian populations. Young white men in nordic countries (northern Europe) have a ten times higher incident rate than black and Asian men.1 GLOBOCAN estimated that about 71,110 new testicular cancer cases and 9510 testicular cancer-related deaths in 2018 as shown in Table 1.

According to the WHO 2016 classification of testicular and para-testicular tissue tumor, germ cell tumors (GCTs) are divided into seminoma and non-seminomatous germ cell tumor (NSGCTs) with the subclass of post-pubertal yolk sac tumor, teratoma, embryonal carcinoma, oricarcinoma and other trophoblastic tumours. GCTs account for 95% of malignant testicular tumor.2–4 It may occasionally occur in the extravaginal primary site yet still managed similarly as testicular GCTs. This neoplasm involves patients of the age of 15 until 35 years old.5,6
Cryptorchidism increases the development of testicular neoplasm by up to eightfold if left untreated or surgically corrected in the post-pubertal phase. The risk of developing neoplasm is, however, only twofold if orchiopexy was done before puberty. The other leading causes are low birth weight, small gestational age, twins, genetics, family history, down syndrome, testicular dysgenesis and testicular microlithiasis. Within the past 40 years, the incidence of these tumors worldwide marked more than double. Additionally, hypercholesterolemia can also be a significant risk factor for various cancers and chronic illness.

Patients of testicular neoplasm typically present with painless testicular enlargement, a vague sense of scrotal heaviness or hydrocele. Classical treatments of testicular cancer are radical inguinal orchiectomy, chemotherapy and radiation therapy which may be done depending on the stage of the neoplasm. The mechanism behind chemotherapy is the activation of autophagy which can cause tumor suppression. Therefore, chemotherapy is the choice treatment in advanced testicular neoplasm. Serum tumor markers like AFP, beta-human chorionic gonadotrophin, lactate dehydrogenase play a pivotal role in the diagnosis and management of testicular neoplasm. However, other potential tumor biomarkers such as microRNAs (miRNAs) and epigenetic markers such as DNMT3A, CALCA and MGMT are usually associated with poor clinical outcome in testicular GCTs.

AFP is an onco-fetal antigen that is clinically beneficial when using together ultrasonography and cross-sectional imaging with MRI or CT of the chest, abdomen and pelvis for preoperative assessment during initial management, early recurrence, or metastases detection upon following up. AFP is found in 90% of cases of prepubertal testicular tumour such as yolk sac tumours. The level of serum AFP is high in the neonates (up to 50,000 ng/ml), drop to normal value by 12 months of age and further decreases with ageing. The normal value of serum AFP is less than 15 ng/ml after one year old. The half-life of AFP is from 5 to 7 days. Any increase in the serum level in an adult may indicate occult NSGCTs, as these tumor markers are produced by NSGCTs but not in pure seminoma. Elevation of serum AFP concentration above 10,000 mg/l in men may also be associated with liver and gall bladder pathology.

β- human chorionic gonadotropin (β-hCG) has a half-life of 1-3 days. It is raised in 10%-20% of clinical stage I(CSI) of NSGCTs cases and raised in 40% of advanced cases. β-hCG is also raised in 15%-20% of advanced seminoma patients. This tumour marker is predominantly raised in choriocarcinoma patients. LDH is an enzyme found in tissues in the body, elevated in 40%-60% of men with testicular GCTs. LDH has less specificity for GCT. Elevated levels are correlated to high tumour burden in seminoma and recurrence in NSGCTs. Assays for LDH does not measure actual quantity but measures enzymatic activity.
Objective and methodology

The key objective of this review article was to determine the role of tumor markers in the diagnosis, staging, prognosis, and management of testicular neoplasm in the current era. We have extensively reviewed the published articles in reputed indexed journals from the year 1970 until 2020 about the various role of tumor markers in managing testicular neoplasm. The popular online databases (such as ScienceDirect, Pubmed, UpToDate, Research Gate, Google Scholar, Nature Review and others) were used to search relevant articles comprehensively.

Table 1: Incidence and mortality of testicular cancer in 2018 by continents*.

| Testicular germ cell carcinoma incidence | Testicular germ cell carcinoma mortality |
|-----------------------------------------|----------------------------------------|
| **Continents**                          | **Male population (thousands)**         | **n** | **ASR** | **n** | **ASR** |
| Eastern Africa                          | 209,604                                | 477   | 0.30    | 226   | 0.17    |
| Middle Africa                           | 84,370                                 | 168   | 0.26    | 79    | 0.15    |
| Northern Africa                         | 119,218                                | 625   | 0.53    | 142   | 0.14    |
| Southern Africa                         | 32,363                                 | 236   | 0.74    | 79    | 0.30    |
| Western Africa                          | 191,785                                | 291   | 0.23    | 154   | 0.16    |
| Caribbean                               | 21,322                                 | 257   | 1.00    | 49    | 0.19    |
| Central America                         | 85,982                                 | 5,281 | 5.50    | 690   | 0.71    |
| South America                           | 208,646                                | 9,801 | 4.20    | 243   | 0.52    |
| North America                           | 180,301                                | 9,459 | 5.10    | 466   | 0.23    |
| Eastern Asia                            | 850,003                                | 7,115 | 0.78    | 1,022 | 0.09    |
| South-eastern Asia                      | 327,352                                | 2,601 | 0.78    | 538   | 0.17    |
| South-central Asia                      | 1,013,759                              | 6,842 | 0.67    | 2,737 | 0.29    |
| Western Asia                            | 141,767                                | 2,794 | 1.80    | 397   | 0.28    |
| Central and eastern Europe              | 138,180                                | 5,505 | 3.50    | 868   | 0.50    |
| Western Europe                          | 95,584                                 | 9,616 | 9.70    | 380   | 0.30    |
| Southern Europe                         | 74,512                                 | 4,904 | 6.70    | 277   | 0.29    |
| Northern Europe                         | 51,925                                 | 3,962 | 7.40    | 121   | 0.19    |
| Australia and New Zealand               | 14,731                                 | 1,097 | 7.20    | 27    | 0.15    |
| Melanesia                               | 5,461                                  | 70    | 1.40    | 12    | 0.28    |
| Polynesia                               | 342                                    | 4     | 1.10    | 0     | 0       |
| Micronesia                              | 272                                    | 0     | 0       | 0     | 0       |
| World                                   | 3,847,487                              | 71,105| 1.7     | 9,507 | 0.23    |

*ASR=age-standardized rate per 100,000 individuals; population size data were retrieved from the department of economic and social affairs, population division, United Nations; (http://esa.un.org/unpd/wpp/Download/Standard/Population).

Table 2: WHO 2016 classification of tumor of the Testis and para-testicular tissue.

| WHO 2016 classification of tumor of the Testis and para-testicular tissue |
|---------------------------------------------------------------|
| **Non-invasive germ cell neoplasia**                          |
| Germ cell neoplasia in situ (GCNIS); previous synonyms: carcinoma in situ testis, intratubular germ cell neoplasia unclassified |
| Gonadoblastoma (in patients with disorders of sex development, also contains sex-stromal elements) |
| **Germ cell tumors derived from GCNIS**                       |
| Seminoma                                                      |
| Non-seminomatous germ cell tumors                             |
| Embryonal carcinoma                                           |
| Teratoma (post-pubertal type)                                 |
| Yolk sac tumor (post-pubertal type)                           |
| Choriocarcinoma and other trophoblastic tumors                |
| **Germ cell tumours unrelated to GCNIS**                      |
| Childhood tumors                                             |
| Teratoma (pre-pubertal type)                                  |
| Yolk sac tumor (pre-pubertal type)                            |
| Spermatocytic tumor (median age of diagnosis around 50 years) |
Table 3: Staging of testicular neoplasm corresponding to a level of tumor.

| SX | No serum tumor markers detected |
|----|--------------------------------|
| S0 | Serum tumor markers are within normal value |
| SI | LDH <1.5x upper limit of normal |
|    | AFP <1000 ng/ml |
|    | β-hCG <5,000 mIU/ml |
| SII | LDH 1.5-10x upper limit of normal |
|    | AFP 1,000-10,000 ng/ml |
|    | β-hCG 5,000-50,000 mIU/ml |
| SIII | LDH >10x upper limit of normal |
|    | AFP >10,000 ng/ml |
|    | β-hCG >50,000 mIU/mL |

Table 4: Prognosis of testicular neoplasm.

| Risk status | Seminoma | Non-seminoma |
|-------------|----------|--------------|
| Good | Stage IIC and III (5 years OS; overall survival rate: 86%) | Stage IIC and IIIA (92% of 5 years OS) |
|    | Any primary sites | Retroperitoneal or Testicular primary tumor |
|    | Without metastasized to non-pulmonary visceral | No metastasized to visceral and non-pulmonary |
|    | Normal AFP | LDH <1.5-10x upper limit of normal+ |
|    | Any LDH | AFP <1000ng/ml |
|    | Any β-hCG | β-hCG <5000 IU/l |
| Intermediate | Stage IIC and III (5 years OS; overall survival rate: 86%) | Stage IIIB (80% of 5 years OS) |
|    | Any primary sites | Retroperitoneal or testicular primary tumor |
|    | Metastasized to non-pulmonary and other visceral | No metastasized to non-pulmonary and visceral |
|    | Normal AFP | LDH 1.5-10x upper limit of normal OR |
|    | Any LDH | AFP 1000-10,000 ng/ml OR |
|    | Any β-hCG | β-hCG: 5000-50,000 IU/l |
|    | - | Stage IIIC (48% of 5 years OS) |
|    | Mediastinal primary tumor OR | Metastasized to non-pulmonary visceral OR |
|    | LDH >10x upper limit of normal OR | AFP >10,000 ng/ml OR |
|    | β-hCG >50,000 IU/l | |

Table 5: Tumor eradication response corresponding to effective chemotherapy.

| Type | Tumour marker | Radio-imaging | Results |
|------|---------------|---------------|---------|
| Type 1 | - | - | No Tumor |
| Type 2 | - | + | Tumor present |
| Type 3 | + | + | Tumor present |
| Type 4 | + + | + + | Disease progression |

DISCUSSION

Application of tumor marker in diagnosis perspective

At least one of the three tumor markers rise in 85% of cases of NSGCT and some seminoma cases. Occasionally, even before the clinical or radiographic manifestation of the disease, there is evidence of an increase in serum tumor markers. Tumor markers are highly crucial in diagnosing testicular cancers and especially, the elevation of serum AFP and β-hCG is very significant to it. Conversely, serum LDH is rarely recommended for diagnostic purpose as it is commonly present in the human body and the rise of it can be associated with other illnesses. It has been proven that patients with an elevated level of LDH have been often classified as false positive for testicular cancer.
Although, as discussed earlier, the rise of AFP and β-hCG indicates testicular cancer, the differential diagnosis for them are pretty vast.\textsuperscript{18} Elevation of AFP during early stages of life in children indicates genetic disorder such as ataxia-telangiectasia and hereditary tyrosinemia. In adults, a malignant condition such as hepatocellular carcinoma is commonly associated with an increased level of AFP.\textsuperscript{19} However, AFP level can also rise in non-neoplastic liver disorders such as alcoholic liver diseases and hepatitis.\textsuperscript{6,14}

In the context of testicular cancers, AFP serum level can be elevated in yolk sac tumors and embryonal carcinoma but not in choriocarcinoma or pure seminoma. Thus, a patient who presents with an evident testicular mass with the rise of AFP is categorized under NSGCT and treated accordingly.\textsuperscript{20}

β-hCG serum level increases by 10 to 20 percent in pure seminoma, all choriocarcinoma and forty to sixty percent in embryonal carcinoma.\textsuperscript{17} Extensive research has been conducted to study the rise of β-hCG. In this research, it is classified into two categories knowingly, if there is a slight elevation of β-hCG, it does not exclusively suggestive of testicular cancer. Contrarily, if there is high elevation β-hCG in the patient's serum, this strongly suggests testicular cancer.\textsuperscript{21}

The elevated level of serum tumor markers should always be correlated with physical examination findings and imaging studies for accurate diagnosis of testicular cancers. However, in conditions where the patient requires urgent treatment or the histological findings are non-specific, the levels of tumor markers can also be helpful for further management.\textsuperscript{20}

Recent studies have been proven that few other markers can also be used for diagnosing testicular cancer. Gamma-glutamyltranspeptidase (GGT), an enzyme primarily used in associated liver diseases, has shown mild elevation in pure seminoma. Placental-like alkaline phosphatase (PLAP) has also shown elevation in pure seminoma, but unfortunately, it can give rise due to other malignancies and smokers.\textsuperscript{15} Thus, this PLAP might be only valuable for non-smokers.\textsuperscript{22} However, a combination of these tumor markers along with AFP, β-hCG and LDH can aid in the diagnosis of pure seminoma and its management.\textsuperscript{23}

Besides, trace elements in a patient's serum such as cobalt, copper, magnesium, lead, zinc, iron and manganese are known to be involved in testicular cancers. Nonetheless, they do involve in other malignancies which could give a vast differential diagnosis.\textsuperscript{24}

Serum molecular biomarkers such as miRNA and circulating mtDNA can be utilized in diagnosing testicular cancers as they are elevated in this solid tumor.\textsuperscript{25} miRNA serves for the sensitivity and specificity rate of 84.7% and 99.0%, whereas mtDNA has the sensitivity of 60% and specificity of 94%, respectively in diagnosing GCTs. miRNA serves as tumor suppressor gene, p53 in testicular cancers and reduce to normal level posts-orchietomy. However, it also elevated in other genitourinary malignancy and thyroid cancers. Furthermore, mtDNA has the potential to distinguish between healthy individuals and cancer patients due to the increasing amount of serum level.\textsuperscript{18} Also, SOX2, a transcription factor, is not present in seminomas and yolk sac tumors but is seen in embryonal carcinomas.\textsuperscript{26} However, further studies needed to verify the support of these tumor biomarkers in handling testicular cancers.

### Staging of testicular neoplasm using serum tumor markers

Tumor staging can be said as the vital principle for monitoring prognosis and treatment in testicular cancer.\textsuperscript{27} Thus, serum tumor markers are utilized in the staging of testicular neoplasm. The staging of testicular neoplasm is mainly divided into three stages; stage I (SI) to stage III (SIII). SIII is the advanced stage of the neoplasm where the tumor spreads to distant lymph nodes such as to the lungs, where it may present with or without increase value in serum tumor markers.

American joint committee on cancer (AJCC) has included serum tumor markers as an additional category in tumor nodes metastases staging, (S). This category is only applied pre-orchietomy. In the 8th edition of AJCC, they included the updated values for each staging (S) of testicular neoplasm, as shown in Table 3.

Clinical staging of NSGCTs is related to the elevated rates of all three serum tumor markers: LDH, AFP and β-hCG in all GCT patients. In the patients with SI disease, if the level of tumour marker fails to return to its normal level, it is considered as clinical-stage Is.\textsuperscript{28} Besides, if the time for serum tumor marker to return to its normal value is rapid after orchietomy, this also suggestive of SI disease.\textsuperscript{29}

While, in men with NSGCTs, post orchietomy, if there is persistent raise of serum markers, these patients must be treated as SIII patients despite having no abnormal findings radiologically.\textsuperscript{30} In a new study, in the group of 442 patients studied, it is discovered that there is an association between measured serum levels of the three markers with clinical stages where the lowest level indicates SI and the highest level indicates SIII.\textsuperscript{28}

LDH rises more in the advanced stage. Therefore, LDH useful in monitoring CSII and CSIII.\textsuperscript{3} Apart from that, serum tumor markers help foretell chances of micro-metastatic disease. A Swedish-Norwegian testicular cancer group discovered that the normal AFP level pre-orchietomy corresponds to a higher risk of retroperitoneal metastasis at retroperitoneal lymph node dissection (RPLND).\textsuperscript{13} Besides, chances of staging error can be reduced with the use of serum tumor markers. This is demonstrated in a study, by using all three serum markers, the staging error is reduced in stage II, from five to ten percent while stage I patients, from fifty-three to around
nine to fourteen percent in embryonal carcinoma of testicular neoplasm.  

**Application of tumor marker in prognosis of testicular neoplasm**

A prognostic factor-based staging system that was published by the international germ cell cancer collaborative group has classified patients into poor, intermediate and reasonable risks. The practical purpose of prognosis is to assess the efficacy of primary chemotherapy regimen, additional therapy, surveillances post-surgery, RPLND, salvage therapy and post-chemotherapy in recurrent cases that influence the outcome of the patient.

Initial therapy responses and duration of initial remission are another crucial prognostic factor. Patients with progressive disease during or within four weeks after completing cisplatin-based chemotherapy are considered a poor diagnosis. Surgical resection following chemotherapy or as primary treatment is highly recommended.

**Application of tumor marker in evaluate response of therapy**

The primary management of testicular cancer involves surgery, chemotherapy and radiotherapy. The common surgeries performed are radical orchietomy and RPLND (if metastasis occurs to retroperitoneal lymph node). In the context of chemotherapy, it is indicated in post-orchietomy (high-risk patients) or for clinical stage II and III patients. As of current treatment, serum tumor markers are obtained on a day before administering each chemotherapy cycle to indicate the effectiveness of previous therapy.

Importantly, stage II testicular tumor, which is only limited to the testis is usually indicated to treat by surgical method. Besides, those with the risks of relapsing can be treated with chemotherapy (RPLND) or surveillance. Outweighing the adverse effects of treatment compared to the curability rate, surveillance is essential. However, patients with a risk of relapsing or relapsed during the surveillance and chemotherapy administration are indicated. Therefore, continuous measurement of serum tumor markers in the period for five years post-orchietomy is required.

Serum tumor markers of the patients are evaluated throughout treatment at different occasions, during the first presentation, before/after radical orchietomy, before initiating each cycle of chemotherapy and during the surveillance period. The tumor eradication response is classified into four types after effective chemotherapy is administered, as shown in the Table 5.

Concurrently, the reduction level of serum tumor marker post-chemotherapy is highly useful in predicting the tumor status. A quick decline after administration of chemotherapy usually produces a cancer-free patient compared to those who decline slowly. On the other hand, a decline of one tumor marker and a consistent rise of the other predicts a mixed type of tumor. To be noted that cancer patients in this current era widely use complementary and alternative medicines. As these medicines interact with chemotherapy, therapeutic failure resulting in alteration of serum tumor marker levels may occur. Thus, an efficient divulgence is needed between healthcare professionals and patients for better outcomes due to the serum tumor marker levels.

**Application of tumor markers in testicular neoplasm relapse detection**

For the early detection of relapse of testicular neoplasm, serum tumor markers can be one of the indicators. Various studies have found evidence of relations between the recurrence rates of testicular neoplasm and the increase of serum tumor marker value, particularly β-hCG and AFP. Any tumor markers that were escalated at the beginning of diagnosis will also be the same marker elevated when the testicular neoplasm relapse. A survey shows that it was specified of relapse of testicular cancer when there is an increase in serum tumor markers after a certain amount of time the serum tumor markers regain their standard value subsequent to the primary therapy of testicular neoplasm. Regardless, this is only probable if there is confirmation of evidence of a primary tumor of the testis.

A Danish study also investigated a cohort of 33 patients with CS-I NSGCTs to assess the rise in LDH-1 pre-orchietomy. It was concluded as anyone who had a normal LDH-1 level is prone to relapse than those with a rise in LDH-1 level pre-orchietomy by 80% to 40%, respectively. LDH level has a role in detecting 40% of all relapses. Besides, it was also found that AFP and β-hCG level played a crucial role in detecting relapse of testicular cancer. The study on a cohort of 32 patients, whereby three patients without β-hCG elevation at beginning of the disease returned with β-hCG elevation when the disease relapse. In late relapse cases, where relapse occurs after two years of disease-free, most of it was recognized by the increase in AFP serum level. Only 10% of patients with NSGCTs have a rise in β-hCG serum level whereby 76 to 52 per cent others dominate in elevation of AFP level. These values can be explained by the discovery of which the most frequent germ cell tumors in patients with relapse are yolk sac tumour. Nevertheless, in the case of testicular teratoma, it is hard to determine whether a patient is disease-free or is relapsing because the serum tumor markers, β-hCG and AFP are both normal at diagnosis and relapse.

Apart from the well-known serum tumor markers discussed above, miRNA has also been found to have a great capability as the latest serum biomarker for detecting relapse of testicular neoplasm. A cluster of miRNAs which is miR-371a-3p is found to be beneficial in detecting...
testicular neoplasm. A group of patients with testicular neoplasm is studied and through this, they noted higher serum levels of miR-371-3p than individuals who are well.37 This is further proved that patient with seminoma who relapse have raised the level of miR-371a-3p whereas patients who are not relapsing do not have raised serum level of miR-371a-3p. However, miR-371a-3p cannot be detected in patients with teratoma.38

CONCLUSION

The ever-growing role of tumor markers in diagnosis, prognosis, staging, response assessment of treatment and relapse of testicular cancer have shown a significant improvement in managing patients with testicular cancers.

Serum AFP, β-hCG and LDH are the known serum tumor markers commonly used in current clinical practice. However, their differential diagnosis is quite vast with limited sensitivity and specificity in pure seminoma. Concerning it, PLAP and GGT, serum trace elements, micro RNA and mitochondrial DNA are yet to be proven biomarkers to be incorporated in germ cell tumours. Nonetheless, research in bigger scales with a greater number of patients need to be done to ensure optimal usage of these biomarkers in diagnosis and management of testicular cancer in future usage in clinical practice.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Park JS, Kim J, Elghiaty, Ham WS. Recent global trends in testicular cancer incidence and mortality. Med. 2018;97(37):12390.
2. Winter C, Albers P. Testicular germ cell tumours: Pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2011;7(1):43-53.
3. Marshall C, Enzerra M, Rahman-McArdle, Ramaiya NH. Serum tumour markers and testicular germ cell tumours: a primer for radiologists. Abdom Radiol. 2019;44:1083-90.
4. Leão R, Ahmad AE, Hamilton RJ. Testicular cancer biomarkers: a role for precision medicine in testicular cancer. Clin Genitourin Cancer. 2019;17(1):176-83.
5. Forman D, Oliver RTD, Brett AR, Marsh SGE, Moses JH, Bodmer JG, et al. Familial testicular cancer: A report of the UK family register, estimation of risk and an HLA class I sib-pair analysis. Br J Cancer. 1992;65(2):255-62.
6. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. Testicular cancer. J Comprenh Cancer Net. 2009;7(6):672-93.
7. Stevenson SM, Lowrance WT. Epidemiology and diagnosis of testis cancer. Urol Clin North Am. 2015;42(3):269-75.
8. Smith ZL, Werntz RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. Med Clin North Am. 2018;102(2):251-64.
9. Ulaganathan V, Kandiah M, Shariff ZM. A case-control study on the association of abdominal obesity and hypercholesterolemia with the risk of colorectal cancer. J Carcinog. 2018;17:4.
10. Rajendran P, Alizahrahni AM, Hanieh HN, Kumar SA, BenAmmar R, Rengarajan T, et al. Autophagy and senescence: a new insight in selected human diseases. J Cell Physiol. 2019;234(12):1-8.
11. Buljubašić R, Buljubašić M, Bojanač AK, Ulamec M, Vlahović M, Ježek D, et al. Epigenetics and testicular germ cell tumors. Gene. 2018;661:22-33.
12. Ahmed HU, Arya M, Munee A, Mushraaq I, Sebire NJ. Testicular and paratesticular tumours in the pre-pubertal population. Lancet Oncol. 2010;11(5):476-83.
13. Masterson TA, Rice KR, Beck SDW. Current and future biochemical markers for disease progression and relapse in testicular germ cell tumours: a review. Urol Oncol Semin Orig Invest. 2014;32(2):261-71.
14. Wahed A, Dasgupta A, Pitfall in testing for common tumour markers. Accur Result Clinic Lab. 2019.
15. Barlow LMI, Badalato GM, McKiernan JM. Serum tumour markers in the evaluation of male germ cell tumours. Nat Rev Urol. 2010;7(11):610-7.
16. Pearson JC, Spaulding JT, Friedman MA. Testicular cancer: role of biological tumour markers. Cancer Treat Rev. 1979;6(4):217-21.
17. Ehrlich Y, Beck SDW, Foster RS, Bihrlre R, Einhorn LH. Serum tumor markers in testicular cancer. Urol Oncol Semin Orig Invest. 2013:31:17-23.
18. Mir MC, Pavan N, Gonzalgo ML. Current clinical applications of testicular cancer biomarkers. Urol Clin North Am. 2016;43(1):119-25.
19. Arifin TK, Sulaiman S, MdSaad S, Damanhuri AH, WanNgah WZ, Mohd YA. Elevation of tumour markers TGF-β, M2-PK, OV-6 and AFP in hepatocellular carcinoma (HCC)-induced rats and their suppression by microalgae Chlorella vulgaris. BMC Cancer. 2017;17:879.
20. Milose JC, Filson CP, Weizer AZ, Hafez KS, Montgomery JS. Role of biochemical markers in testicular cancer: Diagnosis, staging, and surveillance. Open Access J Urol. 2011;4:1-8.
21. Takizawa A, Kishida T, Miura T, Hattori Y, Noguchi K, Kubota Y. Clinical significance of low-level human choriionic gonadotropin in the management of testicular germ cell tumor. J Urol. 2008;179(3):930-5.
22. Nielsen OS, Munro AJ, Duncan W, Sturgeon J, Gospodarowicz MK, Jewett MAS, et al. Is placental alkaline phosphatase (PLAP) a useful marker for seminoma? Eur J Cancer Clin Oncol. 1990;26(10):1049-54.
23. Javadpour N. Multiple biochemical tumour markers in seminoma: a double-blind study. Cancer. 1983;52(5):887-9.
24. Kaba M, Pirinççi N, Yüksel MB, Gecit I, Güneş M, Demir M, et al. Serum levels of trace elements in patients with testicular cancers. Int Braz J Urol. 2015;41(6):1101-7.
25. Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol. 2016;13(12):715-25.
26. Ruf CG, Khalili-Harbi N, Sachs S, Isbarn H, Wagner W, Matthies C, et al. The search for biomarkers of metastatic seminoma. J Urol. 2013;190(3):1046-51.
27. Horwich A, Nicol D, Huddart R. Testicular germ cell tumours. BMJ. 2013;347:1-9.
28. Dieckmann K, Simonsen-Richter H, Kulejewski M, Anheuser P, Zecha H, Isbarn H, et al. Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment. Biomed Res Int. 2019.
29. Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, et al. Testicular cancer. Nat Rev Dis Prim. 2018;4(1):29.
30. Salem M, Gilligan T. Serum tumor markers and their utilization in the management of germ-cell tumors in adult males. Expert Rev Anticancer Ther. 2011;11(1):1-4.
31. Javadpour, N. The role of biologic tumor markers in testicular cancer. Cancer. 1980;45:1755-61.
32. Pectasides D, Pectasides E, Constantinioud A, Aravantinos G. Current management of stage I testicular non-seminomatous germ cell tumours. Crit Rev Oncol Hematol. 2009;70(2):114-23.
33. Al-Naggar RA, Bobryshev YV, Abdulghani MAM, Ram Mohan S, Al-Jashamy K. Knowledge and perceptions of cancer and cancer prevention among Malaysian traditional healers: a qualitative study. Asian Pacific J Cancer Prev. 2012;13(8):3841-50.
34. Venkitaraman R, Johnson B, Huddart RA, CC, Horwich A, Dearnaley DP. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int. 2007;100(1):30-2.
35. Alifrangis C, Lucas O, Benafif S, Ansell W, Greenwood M, Smith S. Management of late relapses after chemotherapy in testicular cancer: optimal outcomes with dose-intense salvage chemotherapy and surgery. Eur Urol Focus. 2020;4(20):1-8.
36. Beck SDW, Foster RS, Bhirle R, Donohue JP. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical stage a nonseminomatous germ cell tumors. Urology. 2007;69(3):557-9.
37. Regouc M, Belge G, Lorch A, Dieckmann K, Pichler M. Non-coding microRNAs as novel potential tumor markers in testicular cancer. Cancers (Basel). 2020;12(3):557-9.
38. Terbuch A, Adiprasito JB, Stiegelbauer V, Seles M, Klec C, Pichler GP, et al. Mir-371a-3p serum levels are increased in recurrence of testicular germ cell tumor patients. Int J Mol Sci. 2018;19(10):3130.

Cite this article as: Banerjee KG, Azlan MHAS, Kalaiarasu L, Nizam HSH. The key application of serum tumor markers in testicular cancer: a review and update. Int J Adv Med 2021;8:844-51.

International Journal of Advances in Medicine | June 2021 | Vol 8 | Issue 6 | Page 851